Dr. Aubrey de Grey: As the Chief Science Officer of the SENS Research Foundation, de Grey is known for his work on rejuvenation biotechnologies and the strategies for engineered negligible senescence (SENS) which aim to prevent age-related diseases.
Dr. David Sinclair: A professor at Harvard Medical School, Sinclair's research delves into the molecular mechanisms of aging. His work on resveratrol and NAD+ precursors has garnered significant attention for their potential anti-aging effects.
Dr. Elizabeth Blackburn: A Nobel laureate recognized for her work on telomeres and the enzyme telomerase, Blackburn's research provides insights into cellular aging and potential interventions to enhance cellular lifespan.
Prof. Judith Campisi: A biogerontologist at the Buck Institute for Research on Aging, Campisi's work focuses on the role of cellular senescence in aging and age-related diseases, aiming to find interventions that target senescent cells.
Dr. Nir Barzilai: As the director of the Institute for Aging Research at the Albert Einstein College of Medicine, Barzilai studies the genetic, metabolic, and biological factors contributing to human longevity.
Dr. Brian Kennedy: Also from the Buck Institute for Research on Aging, Kennedy's research centers on the genetic and environmental factors that modulate aging, with a particular focus on dietary interventions like caloric restriction.
Dr. Maria Blasco: As the head of the Spanish National Cancer Research Centre, Blasco's work is primarily on telomeres and telomerase, studying their roles in both cancer and aging processes.
Dr. Peter Attia: A prominent advocate for lifespan extension and healthspan optimization, Attia delves into the complex interplay of nutrition, sleep, and other lifestyle factors in the aging process.
Dr. Laura Niedernhofer: A researcher at the University of Minnesota, Niedernhofer studies the cellular and molecular mechanisms of aging, aiming to discover therapeutic interventions that can combat age-related decline.
Dr. Alex Zhavoronkov: As the CEO of Insilico Medicine, Zhavoronkov's work combines artificial intelligence and deep learning to discover new drugs and interventions for aging and age-related diseases.
